Advanced search
Publication Cover
Current Medical Research and Opinion Volume 33, 2017 - Issue 5
Submit an article Journal homepage
414
Views
2
CrossRef citations to date
0
Altmetric
Respiratory

Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study

Lei ChenEli Lilly and Company, Indianapolis, IN, USA; Correspondence[email protected]
,
Belen San AntonioLilly España, Madrid, Spain
,
Yu YanEli Lilly and Company, Indianapolis, IN, USA;
,
Jian ChenEli Lilly and Company, Indianapolis, IN, USA;
,
Robert J. GoodloeEli Lilly and Company, Indianapolis, IN, USA;
&
William J. JohnEli Lilly and Company, Indianapolis, IN, USA;
Pages 931-936 | Received 11 Oct 2016, Accepted 09 Jan 2017, Published online: 09 Mar 2017

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Isamu Okamoto, Wolfgang H. W. Schuette, Thomas E. Stinchcombe, José Rodrigues-Pereira, Belén San Antonio, Jian Chen, Jingyi Liu, William J. John & Ralph G. Zinner. (2017) Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies. Current Medical Research and Opinion 33:5, pages 937-941.
Read now

Articles from other publishers (1)

Long-Hua Guo, Ming-Feng Zhang, He-Long Zhang, Jian-Ying Zhou, Xiao-Hong Cai, Yu Long, Qi-Sen Guo, Nong Yang, Jun Zhao, Zhan-Hong Xie, Bo Jiang, Ying Zhu, Yun Fan, Cong-Ying Xie, Yi Hu, Yu Yao, Jun Jia, Xiao-Ling Li, Jiu-Wei Cui, Xi-Zhao Sui, Wen Lin, Ying Cheng, Hui-Juan Wang, Chang-Li Wang, Ming-Fang Zhao, Gui-Bin Qiao, Li-Jun Peng, Lin Yang, Gong-Yan Chen, Kai-Can Cai, Xin-Hua Xu, Liang-Ming Zhang, Guo-Sheng Feng, Jing-Min Zhou, Guo-Wu Wu, Xiao-Rong Dong, Li-Feng Wang, Hong-Mei Zhang, Ya-Jie Gao, Qiu-Ying Jiang, Shun-Dong Cang, Zhi-Xiong Yang, Xia Song, Xiao-Qing Liu, Bo Zhu, Feng-Xia Chen, Chun-Hong Hu, Xi Chen, Yi-Long Wu & Qing Zhou. (2020) Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma. Frontiers in Oncology 10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.